What we’re funding

The Australian Government is investing in health and medical research to support emerging priorities and fill gaps in research effort.

To date the government has announced and invested:

  • $5 million to CanTeen to support new clinical trials for adolescents and young adults with cancer
  • $2 million to the Cure4MND Foundation to support new clinical trials for adults with motor neuron disease (MND)
  • $2 million to the Australian Epilepsy Research Fund to support their SYNGAP-1 research project
  • $2.5 million to the Jean Hailes Foundation to support research priorities identified under the National action Plan for Endometriosis.

Desired outcomes 

The purpose of this research funding is to:

  • improve patient outcomes
  • increase opportunities for patients to take part in clinical trials
  • increase collaboration between peak health organisations and researchers.

Key elements

This program:

  • encourages targeted research in areas of identified unmet need
  • provides funding to peak organisations to fund research activities that actively engage research participants.

Funding recipients will be required to administer their funds consistent with the MRFF Funding Principles.

Why it’s important

  • Adolescents and young adults with cancer have a clinical trial participation rate of 4% to 7%, whereas in other countries participation rates are as high as 30%.
  • The cause of MND is not yet understood and there is no known cure, the average survival rate is 3 to 5 years.
  • Research is emerging that could correct the SYNGAP gene mutation, which is linked to the development of epilepsy, and further funding will ensure sustained effort.
  • Endometriosis has a significant impact on a woman’s life and affects 1 in 10 women worldwide. More research is necessary to better treat and manage the condition.

How to apply

Applications for this program are closed.

Last updated: 
11 July 2018